(NASDAQ: PRCT) Procept Biorobotics's forecast annual revenue growth rate of 24.8% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Procept Biorobotics's revenue in 2026 is $308,054,000.On average, 17 Wall Street analysts forecast PRCT's revenue for 2026 to be $22,863,968,870, with the lowest PRCT revenue forecast at $21,320,005,304, and the highest PRCT revenue forecast at $24,225,228,202. On average, 17 Wall Street analysts forecast PRCT's revenue for 2027 to be $28,453,365,098, with the lowest PRCT revenue forecast at $25,602,840,690, and the highest PRCT revenue forecast at $30,789,047,016.
In 2028, PRCT is forecast to generate $33,684,119,679 in revenue, with the lowest revenue forecast at $31,167,989,133 and the highest revenue forecast at $35,928,449,479.